An observational study in Myocardial Infarction, sponsored by NYU Langone Health. Active, not recruiting at 20 sites in 3 countries. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2026-03-19.
Sponsored by NYU Langone Health · Observational
The HARP study is a multi-center, diagnostic observational study employing standardized imaging protocols in patients with MINOCA (MI with Non Obstructive Coronary Arteries) to determine the underlying diagnosis in each participant. Participants will be followed for recurrent clinical events, every 6 months, for a maximum of 10 years.
HARP is a multi-center, observational study which enrolls men and women with MI who are referred for cardiac catheterization. Eligible participants with MINOCA (defined as no stenosis of >50% in any major epicardial vessel) will undergo optical coherence tomography (OCT) at the time of diagnostic angiography and cardiac magnetic resonance imaging (CMR).
Participants will also have the option to enroll in the HARP-Platelet Sub-Study.
2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.
This study's planned enrollment of 450 is close to the median of 500 across 983 observational studies indexed under Myocardial Infarction.
Browse Myocardial Infarction studies →NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.
Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.
Counted across the registry records on this site, refreshed daily.
Men and women with MI and no coronary stenosis of 50% or greater on angiography, consecutive.
Objective evidence of MI (either or both of the following):
Exclusion Criteria:
OCT and CMR imaging
Device: OCT
Screen failures with MI found to have obstructive CAD. Limited data collection for comparison to MINOCA cohort.
Other: CMR
Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
Proportion of patients with MINOCA who have plaque disruption (any of the following: rupture, erosion, calcified nodule with thrombosis)
Time frame: 1 week
Proportion of patients with MINOCA who have spontaneous coronary dissection.
Time frame: 1 week
Proportion of patients with MINOCA who have late gadolinium enhancement and/or myocardial edema
Time frame: 1 week
Correlation of the presence and location of myocardial abnormalities on CMR with presence and location of plaque disruption on OCT among women with MINOCA.
Time frame: 1 week
Proportion of patients for whom an etiology can be clearly identified after combining OCT and CMR.
Time frame: 1 week
Area under curve of clinical prediction model for plaque disruption on OCT in patients with MINOCA.
Time frame: 1 week
Composite clinical endpoint: Death, unstable angina, stroke, recurrent MI, catheterizations and revascularization, other cardiac hospitalization.
components of composite will also be examined
Time frame: 10 years
Perceived stress
Time frame: 1 week
Plan to share: Yes — De-identified data will be shared after the end of the study.
This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
NYU Langone Health